Clinical Effects of Postoperative Parenteral GlutamineDipeptide Supplementation in Surgical Intensive Care Unit Patients: A Systematic Review and Meta-Analysis
Background: Glutamine plays a vital role as an energy substrate the inflammatory response, prevention of organ injury and renal acid buffering. Parenteral glutamine supplementation could reduce in-hospital and ICU morbidity and mortality.
Objective: Aim of this systematic review and meta-analysis is to investigate the effects of parenteral administration of GLN in adult surgical critically ill ICU patients. Study selection: Two-arm studies about adult surgical ICU patients undergoing postoperative glutamine-enriched parenteral nutrition (experimental cohorts) vs control ones.
Endpoints: Primary endpoint was in-hospital outcome (mortality, length of stay, length of mechanical ventilation). Secondary endpoint was the evaluation of nosocomial infections.
Results: According to PRISMA ® 2020 flow diagram, eight randomized controlled trials were included for a total of 603 patients. No significant differences about in-hospital and ICU mortality were found (p=0.16 and p=0.53, respectively). Parenteral glutamine-supplementation was associated with a reduction of hospitalization (p=0.02), without influencing nor ICU stay (p=0.35) neither postoperative mechanical ventilation (p=0.18). Finally, dipeptide administration did not reduced cumulative incidence of nosocomial infections (p=0.41); however, a protective role for postoperative pneumonia was reported (p=0.05).
Conclusions: Excepting for a reduction in hospital stay and incidence of nosocomial pneumonia, glutamine-dipeptide parenteral supplementation does not add any benefit in surgical ICU patients.
1. Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev 1990;48:297–309.
2. Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients 2018;10:1564.
3. Wilmore DW. The effect of glutamine supplementation in patients following elective surgery and accidental injury. J Nutr 2001;131:2543S–9S; discussion 2550S–1S.
4. Heyland D, Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013;368:1489–97.
5. Rodas PC, Rooyackers O, Hebert C, Norberg Å, Wernerman J. Glutamine and glutathione at ICU admission in relation to outcome. Clin Sci (Lond) 2012;122:591–7.
6. Déchelotte P, Hasselmann M, Cynober L, Allaouchiche B, Coëffier M, Hecketsweiler B, et al. L-alanyl-L-glutamine dipeptidesupplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. Crit Care Med 2006;34:598–604.
7. Smedberg M, Wernerman J. Is the glutamine story over? Crit Care 2016;20:361.
8. Deitch EA. Gut-origin sepsis: evolution of a concept. Surgeon 2012;10:350–6.
9. Wernerman J, Kirketeig T, Andersson B, Berthelson H, Ersson A, Friberg H, et al; Scandinavian Critical Care Trials Group. Scandinavian glutamine trial: a pragmatic multi-centre randomised clinical trial of intensive care unit patients. Acta Anaesthesiol Scand 2011;55:812–8.
10. Andrews PJ, Avenell A, Noble DW, Campbell MK, Croal BL, Simpson WG, et al; Scottish Intensive care Glutamine or seleNium Evaluative Trial Trials Group. Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients. BMJ 2011;342:d1542
11. Yarandi SS, Zhao VM, Hebbar G, Ziegler TR. Amino acid composition in parenteral nutrition: what is the evidence? Curr Opin Clin Nutr Metab Care 2011;14:75–82.
12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
13. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37–46
14. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
16. Goeters C, Wenn A, Mertes N, Wempe C, Van Aken H, Stehle P, et al. Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients. Crit Care Med 2002;30:2032–7.
17. Fuentes-Orozco C, Anaya-Prado R, González-Ojeda A, ArenasMárquez H, Cabrera-Pivaral C, Cervantes-Guevara G, et al. L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. Clin Nutr 2004;23:13–21.
18. Ziegler TR, Ogden LG, Singleton KD, Luo M, Fernandez-Estivariz C, Griffith DP, et al. Parenteral glutamine increases serum heat shock protein 70 in critically ill patients. Intensive Care Med 2005;31:1079–86.
19. Kumar S, Kumar R, Sharma SB, Jain BK. Effect of oral glutamine administration on oxidative stress, morbidity and mortality in critically ill surgical patients. Indian J Gastroenterol 2007;26:70–3.
20. Estívariz CF, Griffith DP, Luo M, Szeszycki EE, Bazargan N, Dave N, et al. Efficacy of parenteral nutrition supplemented with glutamine dipeptide to decrease hospital infections in critically ill surgical patients. JPEN J Parenter Enteral Nutr 2008;32:389–402.
21. Cekmen N, Aydin A, Erdemli O. The impact of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on clinical outcome in critically patients. e-SPEN, Euro e-J Clin Nutr Metab 2011;6:64–7.
22. Ziegler TR, May AK, Hebbar G, Easley KA, Griffith DP, Dave N, et al. Efficacy and safety of glutamine-supplemented parenteral nutrition in surgical ICU patients: An American multicenter randomized controlled trial. Ann Surg 2016;263:646–55.
23. Curi R, Lagranha CJ, Doi SQ, Sellitti DF, Procopio J, Pithon-Curi TC, et al. Molecular mechanisms of glutamine action. J Cell Physiol 2005;204:392–401.
24. Biolo G, Zorat F, Antonione R, Ciocchi B. Muscle glutamine depletion in the intensive care unit. Int J Biochem Cell Biol 2005;37:2169–79.
25. Hirose T, Shimizu K, Ogura H, Tasaki O, Hamasaki T, Yamano S, et al. Altered balance of the aminogram in patients with sepsis - the relation to mortality. Clin Nutr 2014;33:179–82.
26. Smedberg M, Helleberg J, Norberg Å, Tjäder I, Rooyackers O, Wernerman J. Plasma glutamine status at intensive care unit admission: an independent risk factor for mortality in critical illness. Crit Care 2021;25:240.
27. Pérez-Bárcena J, Crespí C, Regueiro V, Marsé P, Raurich JM, Ibáñez J, et al. Lack of effect of glutamine administration to boost the innate immune system response in trauma patients in the intensive care unit. Crit Care 2010;14:R233.
28. Cetinbas F, Yelken B, Gulbas Z. Role of glutamine administration on cellular immunity after total parenteral nutrition enriched with glutamine in patients with systemic inflammatory response syndrome. J Crit Care 2010;25:661.e1–6.
29. Chen QH, Yang Y, He HL, Xie JF, Cai SX, Liu AR, et al. The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials. Crit Care 2014;18:R8.
30. Pimentel RFW, Fernandes SL. Effects of parenteral glutamine in critically ill surgical patients: a systematic review and metaanalysis. Nutr Hosp 2020;34:616–21.
31. Frediani JK, Jones DP, Tukvadze N, Uppal K, Sanikidze E, Kipiani M, et al. Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study. PLoS One 2014;9:e108854.
32. Langley RJ, Tsalik EL, van Velkinburgh JC, Glickman SW, Rice BJ, Wang C, et al. An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med 2013;5:195ra95.
33. Rogers AJ, McGeachie M, Baron RM, Gazourian L, Haspel JA, Nakahira K, et al. Metabolomic derangements are associated with mortality in critically ill adult patients. PLoS One 2014;9:e87538.